| Field | Specification |
|---|---|
| Target | |
| UniProt # | |
| CAS no. | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Purity | |
| Reconstitution | |
| Form | Liquid |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
felmetatug (HV721116) is a research-grade recombinant antibody targeting VTCN1/B7-H4. Highlights- Research Grade — For PK/PD studies, assay development, and ADA research.
Specifications
| Host Species | Human |
|---|---|
| Species Reactivity | Human |
| Clonality | Monoclonal |
| Isotype | IgG1, kappa |
| Target | VTCN1/B7-H4 |
| Purity | >95% purity as determined by SDS-PAGE. |
| Form | Liquid |
| UniProt | Q7Z7D3 |
Validated Applications
| Application |
|---|
| ELISA |
| Flow Cytometry |
| Functional Assay |
| In Vivo Studies |
Scientific Background
V-set domain-containing T-cell activation inhibitor 1 (VTCN1/B7-H4) is a ~30 kDa protein. Negatively regulates T-cell-mediated immune response by inhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity. When expressed on the cell surface of tumor macrophages, plays an important role, together with regulatory T-cells (Treg), in the suppression of tumor-associated antigen-specific T-cell immunity. Involved in promoting epithelial cell transformation.
Reactivity
This antibody shows reactivity with Human.
Safety & Handling
Customization & Add-ons: Can't find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
